<DOC>
	<DOCNO>NCT00871585</DOCNO>
	<brief_summary>Prospective , non-comparative , non-interventional , observational study collect analyse real life environment data advance prostate cancer patient receive combination treatment medical surgical castration bicalutamide accord routine medical practice Croatia . The main aim evaluate change PSA level prescribe practice base prostate cancer stage .</brief_summary>
	<brief_title>Evaluation Prostate-Specific Antigen ( PSA ) Levels Patients With Advanced Prostate Cancer Treated With Bicalutamide</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Patients diagnosis advanced prostate cancer Patients already treat bicalutamide least 4 week maximum 12 week Patients capable sign ICF Patients hypersensitivity bicalutamide Patients therapy terfenadin , astemizol cisapride Participation clinical study last 30 day</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>bicalutamide</keyword>
	<keyword>PSA</keyword>
	<keyword>advanced prostate cancer</keyword>
</DOC>